Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
54 hedge funds and large institutions have $599M invested in Soleno Therapeutics in 2023 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 5 closing their positions.
2,646% more capital invested
Capital invested by funds: $21.8M → $599M (+$577M)
620% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 5
140.82% more ownership
Funds ownership: 62.4% → 203.22% (+141%)
135% more funds holding
Funds holding: 23 → 54 (+31)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$19.4M |
| 2 |
Janus Henderson Group
London,
|
+$13.3M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.03M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$7.5M |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$6.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$1.56M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.56M |
| 3 |
BC
Birchview Capital
Burlington,
Vermont
|
-$1.05M |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$390K |
| 5 |
JGC
J. Goldman & Co
New York
|
-$332K |
SLNO Hedge Fund Activity: Q3 2023 in Review
54 of the 6,304 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q3 2023, worth a combined $599M — up 2,646% from $21.8M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new SLNO positions and 5 closed out — a net gain of 31 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $19.4M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $1.56M sold.
- 54 institutional investors held Soleno Therapeutics (SLNO) as of Q3 2023, up from 23 in Q2 2023.
- Funds reported $599M of Soleno Therapeutics stock for Q3 2023, up 2,646% quarter-over-quarter.
- 36 funds opened new Soleno Therapeutics positions in Q3 2023 and 5 closed out, a net change of +31 holders.
- The largest Soleno Therapeutics buyer in Q3 2023 was Vivo Capital, an estimated $19.4M added.
- The largest Soleno Therapeutics seller in Q3 2023 was AIGH Capital Management, an estimated $1.56M sold.
Based on aggregated 13F filings for Q3 2023.